References
- Rait L L. Systemic effects of topical ophthalmic β-adrenoceptor antagonists. Australian and New Zealand Journal of Ophthalmology 1999; 27: 57–64
- McMahon C D, Shaffer R N, Hoskins H D, Hetherington J. Adverse effects experienced by patients taking timolol. American Journal of Ophthalmology 1979; 88: 736–738
- Shore J H, Fraunfelder F T, Meyer S M. Psychiatric side-effects from topical ocular timolol, a beta-adrenergic blocker. Journal of Clinical Psychopharmacology 1987; 7: 264–267
- Bourgeois J A. Depression and topical ophthalmic beta adrenergic blockade. Journal of the American Optometry Association 1991; 62: 403–406
- Orlando R G. Clinical depression associated with betaxolol. American Journal of Ophthalmology 1986; 102: 275
- Bright R A, Everitt D E. β-blockers and depression. Journal of the American Medical Association 1992; 267: 1783–1787
- Vetulani J. Current concepts of mechanisms of action of antidepressant treatments based on preclinical studies. Basic and clinical science of mental and addictive disorders (Bibliotheca Psychiatrica 167), L L Judd, B Saletu, V Filip. Karger, Basel 1997; 162–167
- Andree B, Thorberg S O, Halldin C, Farde L. Pindolol binding to 5HT1A receptors in human brain confirmed with positron emission tomography. Psychopharmacology 1999; 144: 303–305
- Gobert A, Millan M J. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5HT) in the frontal cortex of freely-moving rats by (-) -pindolol alone and in association with 5HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology 1994; 21: 268–284
- Edeki T I, He H, Wood A JJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral–ophthalmic drug interaction. Journal of the American Medical Association 1995; 274: 1611–1613